SCHEMBL15946014

SCHEMBL15946014

CCCC(O)c1cccc(NCCCCCOC)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 2/20 0.39
ADRB1 P08588 2/20 0.39
ADRB3 P13945 2/20 0.39
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
AOC3 Q16853 1/20 0.36
KDM4E B2RXH2 2/20 0.36
F2R P25116 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35
KCNH3 Q9ULD8 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2150441 0.89 AOC3 (0.39) ADRB2ADRB1ADRB3PRMT5WDR77
SCHEMBL15945986 0.87 KDM4E (0.44) ADRB2ADRB1ADRB3KDM4EF2R
SCHEMBL15945987 0.86 ALDH1A1 (0.46) ADRB2ADRB1ADRB3KDM4EF2R
SCHEMBL15946000 0.84 ADRB2 (0.47) ADRB2ADRB1ADRB3KDM4ESMN1; SMN2
SCHEMBL2151461 0.83 ADRB2 (0.37) ADRB2ADRB1ADRB3PRMT5WDR77
SCHEMBL13323561 0.80 ADRB3 (0.43) ADRB2ADRB1ADRB3KDM4E
SCHEMBL2151025 0.79 ALDH1A1 (0.36) ADRB2ADRB1ADRB3PRMT5WDR77
SCHEMBL15576272 0.79 LMNA (0.47) KDM4EL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL2150673 0.78 KDM4E (0.41) KDM4EF2R
SCHEMBL10235729 0.78 LPL (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145198-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. 2016-05-26 US disclosed
US-9193669-B2 Compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2015-11-24 US disclosed
US-20140228443-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. (US) 2014-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145198-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS PDE6D, CLN6, ALDH1A2 ADRB2 996/4885ADRB1 856/4885ADRB3 763/4885
US-20140228443-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS PDE6D, CLN6, ALDH1A2 ADRB2 996/4885ADRB1 856/4885ADRB3 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.